Developing a next-generation vaccine that drives (a) more durable and broad anti-spike neutralizing antibodies (NABS) against variants of concern (VOCS), including those not included in the vaccine,…
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50123C00062
- Awardee
-
Gritstone Bio, Inc. UEI WPNLFZK8MA87
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $9,856,008
Award facts
- Opportunity
-
- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) Pre-Solicitation · BAA18100SOL00003 · Posted Oct 16, 2017
- Contract value 2% obligated
-
- $9,856,008.00 Current, with exercised options
- $433,190,532.00 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Boston, MA 02215, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $9,856,008 |
About this award
Gritstone Bio, Inc. was awarded a $433.2 million cost-plus-fixed-fee definitive contract by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to develop a next-generation vaccine designed to elicit durable and broad anti-spike neutralizing antibodies against variants of concern, including those not represented in the vaccine formulation, while simultaneously generating T cells reactive against conserved targets. The contract, awarded on September 25, 2023, with performance based in Boston, Massachusetts, carries an ultimate completion date of July 2, 2026, and includes no set-aside designation.
This award originated from a Broad Agency Announcement issued by the Biomedical Advanced Research and Development Authority (BARDA) in October 2017, which sought proposals for advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and pandemic influenza threats. The solicitation encompassed multiple focus areas including vaccines, therapeutics, diagnostics, and related technologies to advance candidates toward FDA approval or licensure. Gritstone Bio's vaccine development effort aligns with BARDA's core mission of accelerating the development of medical countermeasures to address emerging pandemic and biological threats, leveraging ASPR's resources to support the advancement of critical public health capabilities.
Description
Developing a next-generation vaccine that drives (a) more durable and broad anti-spike neutralizing antibodies (NABS) against variants of concern (VOCS), including those not included in the vaccine, and (B) T cells reactive against conserved targets
Quick answers
Who was awarded contract 75A50123C00062?
75A50123C00062 was awarded to Gritstone Bio, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 25, 2023.
How much is contract 75A50123C00062 worth?
The government has obligated $9,856,008 on 75A50123C00062. Its potential value, with all options, is $433,190,532.
Was contract 75A50123C00062 competed?
The extent of competition for 75A50123C00062 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award